Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...

It has been less than two months since my previous article on Halozyme Therapeutics (NASDAQ:HALO), where I highlighted the company's impressive Q3 earnings and recapped my views on the company's ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00.Stay Ahead ...

Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due ...

Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $54.51 which represents a slight increase of $0.68 or 1.26% from the prior close of $53.83. The stock opened at $54.39 ...

Halozyme Therapeutics (HALO) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows that ...

In the last three months, 11 analysts have published ratings on Halozyme Therapeutics (NASDAQ:HALO), offering a diverse range of perspectives from bullish to bearish. The table below offers a ...